Phase 3 results showed the treatment nearly doubled survival for patients with previously treated metastatic pancreatic cancer.
An experimental drug for metastatic pancreatic cancer nearly doubled overall survival in a Phase 3 clinical trial, offering new hope for patients with one of the deadliest forms of cancer.
The findings, presented Sunday at the American Society of Cli... [3506 chars]